Therapeutic strategies aimed at modulating the immune microenvironment, particularly macrophage activity and cytokine production, hold promise for mitigating resistance and improving patient outcomes in melanoma treated with BRAF/MAPK-targeted therapies. This evidence concerns the gene BRAF and melanoma.